Today's Sponsored Feature is part of your subscription to the daily AAP SmartBrief. This feature, produced by SmartBrief and a select group of sponsors, highlights issues, products and services of interest to pediatricians and other child health professionals. It also allows for continued free delivery of AAP SmartBrief. Thank you for your interest.

-- The AAP SmartBrief Team


SPONSORED FEATURE
FEATURED ARTICLE
FEATURED ARTICLE
Faster diagnoses through genomic testing

The Center for Pediatric Genomic Medicine at Children's Mercy was created to help unlock the mysteries of pediatric genetic diseases. A physician must attempt to solve many mysteries when diagnosing a child's illness. With over 8,000 genetic diseases, the clinical detective work can call for a vast number of tests which can continue for years.

Read more here.
TaGSCAN used to diagnose more than 750 diseases

Researchers at Children's Mercy have developed TaGSCAN (Targeted Gene Sequencing and Custom Analysis), one test that screens for more than 750 diseases that are the result of a single-gene defect. These include hundreds of diseases that have either been challenging to diagnose or for which no test has been available.

Read more here.
COMPANY PROFILE
Children's Mercy, located in Kansas City, Mo., is an independent, 354-bed pediatric health system, serving half a million patients each year from across the country. Children's Mercy has been ranked by U.S. News & World Report as one of "America's Best Children's Hospitals" and received Magnet recognition three times for excellence in nursing services.

In affiliation with the University of Missouri-Kansas City, our faculty of nearly 600 pediatric subspecialists and researchers are actively involved in clinical care, pediatric research, and educating the next generation of pediatric subspecialists. And our leadership in pediatric genomic medicine and clinical pharmacology is driving research and innovation in neonatology, heart care, cancer treatment and other subspecialties to transform outcomes for children here and around the world.
RESOURCE CENTER
RELEVANT RESEARCH
World's fastest whole-genome test for newborns

STAT-Seq uses software developed at Children's Mercy which translates physician-entered clinical features in individual patients into a comprehensive differential diagnosis of relevant diseases. This software substantially automates identification of the DNA variations that can explain the child's condition.

Read more here.
SMARTBRIEF ARCHIVES: RELATED NEWS
  • Scientists ponder how to handle data from baby genome mapping
    Scientists in Boston, San Francisco, Chapel Hill, N.C., and Kansas City, Mo., will be working on an NIH-funded project to map newborns' genomes in an effort to explore different ways the technology might be used. Two studies will explore the kinds of information parents want about their babies, one will identify gene sets important in childhood, and one will test whether rapid gene-mapping can speed diagnosis of sick infants. Yahoo/The Associated Press (10/7)
  • Study: Relatively few gene mutations drive most cancers
    Researchers working on the Cancer Genome Atlas project analyzed 3,281 tumors from 12 cancer types and found 127 mutated genes associated with tumor formation or progression. The results, published in the journal Nature, may help scientists develop drugs that precisely target specific mutations. Bloomberg (10/16)
  • Study links children's obesity risk to gene mutation
    Children with mutations in the KSR2 gene exhibited greater appetites and slower metabolism compared with those who did not have the mutations, British researchers found. "This work adds to a growing body of evidence that genes play a major role in influencing a person's weight and may be useful for developing new ways to treat people who are heavy and develop diabetes," study author Sadaf Farooqi said. U.S. News & World Report/HealthDay News (10/24)
  • Genetic variation in GATA3 tied to increased risk of childhood lymphoblastic leukemia
    Children who inherited a high-risk variant in the GATA3 gene were almost four times more likely to develop Philadelphia chromosome-like acute lymphoblastic leukemia than those with a different genetic variation, a study in the journal Nature Genetics showed. The high-risk gene variant was also associated with poor treatment response as well as increased recurrence risk. Oncology Nurse Advisor online (11/5)
What is this?A Sponsored Feature is an advertorial that includes valuable content provided by the sponsor and editorial materials from SmartBrief's archives. This Sponsored Feature does not represent an endorsement by the AAP or SmartBrief, Inc. of the products and services offered. If you unsubscribe from this Sponsored Feature, you will not be unsubscribing from all other editions of the AAP SmartBrief.
Subscriber Tools:
Sign up for AAP SmartBrief | Send Feedback | Email this brief | Unsubscribe from AAP SmartBrief Sponsored Features
Advertising with SmartBrief:Associate Healthcare Publisher Aaron Kern 202-407-7866
Mailing Address:SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.®  Legal Information.